The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II trial of prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-refractory metastatic castration-resistant prostate cancer (mCRPC).
Daniel Peter Petrylak
Research Funding - Progenics
David C. Smith
Research Funding - Progenics
Leonard Joseph Appleman
Research Funding - Progenics
Mark T. Fleming
Research Funding - Progenics
Arif Hussain
Research Funding - Progenics
Robert Dreicer
Research Funding - Progenics
A. Oliver Sartor
Research Funding - Progenics
Neal D. Shore
Research Funding - Progenics
Nicholas J. Vogelzang
Research Funding - Progenics
Hagop Youssoufian
Employment or Leadership Position - Progenics
Stock Ownership - Progenics
William C. Olson
Employment or Leadership Position - Progenics
Stock Ownership - Progenics
Nancy Stambler
Employment or Leadership Position - Progenics
Stock Ownership - Progenics
Kathleen Huang
Employment or Leadership Position - Progenics
Robert Joseph Israel
Employment or Leadership Position - Progenics
Stock Ownership - Progenics